Emcure Pharmaceuticals has released its investor presentation for the financial year ending March 31, 2026, on BSE.
Emcure Pharmaceuticals has submitted its investor presentation to NSE, providing stakeholders with updated corporate information.
Emcure Pharmaceuticals has recommended a final dividend for the financial year 2025-26, subject to shareholder approval at the upcoming annual general meeting.
Emcure Pharmaceuticals board has recommended a final dividend for FY 2025-26. The proposal awaits shareholder approval at the upcoming annual general meeting.
NSE & BSE filings, earnings, insider trades, and smart volume alerts — on WhatsApp or Telegram. No separate app to install.